Extent of pathological damage to animals in a cold environment who are explosively decompressed.

H. G. Clamann,H. Adler,U. Luft

1947-10-01

Abstract:

What problem does this paper attempt to address?

Mitochondrial Lon Protease and Cancer.

Bin Lu

DOI: https://doi.org/10.1007/978-981-10-6674-0_12

2017-01-01

Abstract:ATP-dependent Lon protease of mitochondrial matrix is encoded by nuclear DNA and highly evolutionarily conserved throughout all organisms, which is involved in the quality control of proteins by selective degradation of misfolded, oxidized, and short-lived regulatory proteins within mitochondrial matrix, maintenance of mitochondrial genome (mtDNA), and folding of mitochondria proteins. Various stimuli such as hypoxia and oxidative and ER stress lead to upregulation of Lon expression. Inhibition of protease activity or downregulation of Lon promotes cancer cell death and enhances sensitivity of cancer cells to anticancer drugs through metabolic reprogramming, thus reducing the viability of cancer cell in tumor microenvironment and epithelial to mesenchymal transition (EMT). Moreover, mitochondrial ATP-dependent Lon protease may serve as a potential biomarker for cancer diagnosis and novel target for the development of anticancer drugs and for predicting of the efficiency and effectiveness of chemotherapy of a variety of cancers.
The Mitochondrial Unfoldase-Peptidase Complex ClpXP Controls Bioenergetics Stress and Metastasis

Jae Ho Seo,Dayana B Rivadeneira,M Cecilia Caino,Young Chan Chae,David W Speicher,Hsin-Yao Tang,Valentina Vaira,Silvano Bosari,Alessandro Palleschi,Paolo Rampini,Andrew V Kossenkov,Lucia R Languino,Dario C Altieri

DOI: https://doi.org/10.1371/journal.pbio.1002507

2016-07-07

Abstract:Mitochondria must buffer the risk of proteotoxic stress to preserve bioenergetics, but the role of these mechanisms in disease is poorly understood. Using a proteomics screen, we now show that the mitochondrial unfoldase-peptidase complex ClpXP associates with the oncoprotein survivin and the respiratory chain Complex II subunit succinate dehydrogenase B (SDHB) in mitochondria of tumor cells. Knockdown of ClpXP subunits ClpP or ClpX induces the accumulation of misfolded SDHB, impairing oxidative phosphorylation and ATP production while activating "stress" signals of 5' adenosine monophosphate-activated protein kinase (AMPK) phosphorylation and autophagy. Deregulated mitochondrial respiration induced by ClpXP targeting causes oxidative stress, which in turn reduces tumor cell proliferation, suppresses cell motility, and abolishes metastatic dissemination in vivo. ClpP is universally overexpressed in primary and metastatic human cancer, correlating with shortened patient survival. Therefore, tumors exploit ClpXP-directed proteostasis to maintain mitochondrial bioenergetics, buffer oxidative stress, and enable metastatic competence. This pathway may provide a "drugable" therapeutic target in cancer.
Abstract 446: LONP1 inhibition induces mitochondrial proteotoxic stress and is cytotoxic to acute myeloid leukemia cells

Matthew Tcheng

DOI: https://doi.org/10.1158/1538-7445.am2023-446

IF: 11.2

2023-04-04

Cancer Research

Abstract:Abstract Acute myeloid leukemia (AML) is a hematological malignancy characterized by the uncontrolled proliferation of abnormal myeloid precursors that fail to fully differentiate, resulting in the accumulation of malignant leukemic cells. High rates of nuclear-encoded protein synthesis, supporting increased proliferation rates, render leukemic cells reliant on increased proteolytic systems to clear misfolded proteins. Compared to non-transformed blood cells, AML cells and stem cells exhibit a unique metabolic phenotype characterized by increased mitochondrial mass and greater reliance on oxidative metabolism for survival and proliferation. To identify novel biological vulnerabilities in the mitochondrial proteome, we analyzed the DepMap (depmap.org) for essential mitochondrial genes in AML. Through this analysis, we identified the mitochondrial protease LONP1 as essential for a subset of AML and in the top 10% of essential genes for this disease. LONP1 is a nuclear-encoded AAA+ serine protease that resides in the mitochondrial matrix and maintains the mitochondrial proteome, mainly via the clearance of misfolded, unassembled or oxidatively-damaged proteins. However, its importance and function in AML has not been previously reported. Compared to normal hematopoietic cells, LONP1 mRNA was overexpressed in AML across three publicly available datasets while LONP1 protein was increased >2 fold in tested AML primary samples (N=16). Using shRNA and CRISPR gRNA, LONP1 knockdown and knockout reduced the growth and viability of OCI-AML2, OCI-M2, and NB4 cells. Mechanistically, genetic knockdown or knockout of LONP1 increased levels of insoluble, aggregated mitochondrial proteins including ClpP, TUFM, and NDUFA9 as measured by immunoblotting of soluble and insoluble protein fractions as well as by the fluorescence of the protein aggregation dye PROTEOSTAT by confocal microscopy. The accumulation of insoluble mitochondrial protein aggregates through LONP1 inhibition exploits an increased reliance on chaperone and protease systems due to abnormally high protein synthesis. This novel therapeutic avenue targets a unique metabolic vulnerability to eliminate AML cells. Citation Format: Matthew Tcheng. LONP1 inhibition induces mitochondrial proteotoxic stress and is cytotoxic to acute myeloid leukemia cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 446.

oncology
Annual Meeting of the Pediatric Orthopaedic Society of North America, Miami, Florida, April 30-May 4, 1995.

R. Hensinger

DOI: https://doi.org/10.1097/01241398-199511000-00026

1995-11-01

Journal of Pediatric Orthopedics

Abstract:
Abstract 5898: Inhibition of the LONP1 ATPase domain induces mitochondrial proteotoxic stress and is cytotoxic to acute myeloid leukemia cells

Matthew Tcheng,Marcela Gronda,Rose Hurren,Lan Xin Zhang,Chaitra Sarathy,Yongran Yan,Andrea Arruda,Mark D. Minden,Aaron D. Schimmer

DOI: https://doi.org/10.1158/1538-7445.am2024-5898

IF: 11.2

2024-03-31

Cancer Research

Abstract:Compared to normal hematopoietic cells, AML cells exhibit a heightened reliance on mitochondrial metabolism for survival and proliferation. To support this unique phenotype, AML cells increase import of nuclear-encoded mitochondrial proteins which must be properly folded by mitochondrial chaperones, proteases, and heat shock proteins. Failure to properly fold these precursors leads to protein aggregation, mitochondrial dysfunction, and cell death. To evaluate the reliance of AML cells on maintaining mitochondrial proteostasis, we assessed gene dependency datasets (eg: depmap.org) and identified the mitochondrial protease LONP1, as the top essential gene. LONP1 is a matrix-localized nuclear-encoded AAA+ protease. Proteins are unfolded by its ATPase domain and degraded by its serine-catalyzed proteolytic domain. Compared to hematopoietic cells, LONP1 mRNA was overexpressed in AML across three publicly available datasets. By immunoblotting, LONP1 protein was increased in 16/30 primary AML samples compared to bulk (n=8) and CD34+ blood cells (n=3). LONP1 genetic depletion reduced the growth and viability of OCI-AML2, OCI-M2, NB4, and TEX leukemia cells as well as primary AML cells. LONP1 depletion increased aggregated mitochondrial proteins and reactive oxygen species (ROS) production while reducing mitochondrial respiration and membrane potential. To determine the domain of LONP1 that was necessary for mitochondrial protein solubility, mitochondrial function, and AML survival, we over-expressed wild type, ATPase dead (E591A), or proteolytically dead (S855A) LONP1 cDNA in OCI-AML2 cells and knocked down endogenous LONP1 with shRNA targeting the 3'UTR of the endogenous gene. Wild type or proteolytically dead (S855A) but not the ATPase mutant (E591A) rescued mitochondrial protein solubility, mitochondrial respiration, ROS generation, membrane potential, and cell viability. Thus, the ATPase domain but not the proteolytic activity of LONP1 is necessary for mitochondrial proteostasis. Bardoxolone methyl (CDDO-Me) is a synthetic triterpenoid that allosterically inhibits the LONP1 ATPase site. CDDO-Me killed OCI-AML2 and NB4 cells with IC50 values of 178.5±29.7 and 156.5±39.7 nM, respectively. CDDO-Me (200 nM) killed 3 out of 4 primary AML samples with high LONP1 expression but none of the 10 primary AML samples with low LONP1. Likewise, CDDO-Me induced mitochondrial protein aggregation in AML cell lines and primary AML patient samples with high LONP1 expression but not AML cells or primary AML patient samples with low LONP1. In summary, LONP1 is over-expressed in a subset of AML cells and primary samples where it maintains mitochondrial protein solubility. Selective inhibition of the LONP1 ATPase domain leads to mitochondrial protein aggregation and AML cell death, representing a novel therapeutic strategy for AML. Citation Format: Matthew Tcheng, Marcela Gronda, Rose Hurren, Lan Xin Zhang, Chaitra Sarathy, Yongran Yan, Andrea Arruda, Mark D. Minden, Aaron D. Schimmer. Inhibition of the LONP1 ATPase domain induces mitochondrial proteotoxic stress and is cytotoxic to acute myeloid leukemia cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 5898.

oncology
HSP60-regulated Mitochondrial Proteostasis and Protein Translation Promote Tumor Growth of Ovarian Cancer

Jianying Guo,Xiao Li,Wenhao Zhang,Yuling Chen,Songbiao Zhu,Liang Chen,Renhua Xu,Yang Lv,Di Wu,Mingzhou Guo,Xiaohui Liu,Weiguo Lu,Haiteng Deng

DOI: https://doi.org/10.1038/s41598-019-48992-7

IF: 4.6

2019-01-01

Scientific Reports

Abstract:Ovarian cancer (OC) is the most lethal gynecological carcinoma due to the lack of diagnostic markers and effective drug targets. Discovery of new therapeutic targets in OC to improve the treatment outcome is urgently needed. We performed proteomic analysis of OC specimens and the paired normal tissues and revealed that proteins associated with mitochondrial proteostasis and protein translation were highly expressed in ovarian tumor tissues, indicating that mitochondria are required for tumor progression of OC. Heat shock protein 60 (HSP60), an important mitochondrial chaperone, was upregulated in ovarian tumors. HSP60 silencing significantly attenuated growth of OC cells in both cells and mice xenografts. Proteomic analysis revealed that HSP60 silencing downregulated proteins involved in mitochondrial functions and protein synthesis. Metabolomic analysis revealed that HSP60 silencing resulted in a more than 100-fold increase in cellular adenine levels, leading to increased adenosine monophosphate and an activated AMPK pathway, and consequently reduced mTORC1-mediated S6K and 4EBP1 phosphorylation to inhibit protein synthesis that suppressed the proliferation of OC cells. These results suggest that HSP60 knockdown breaks mitochondrial proteostasis, and inactivates the mTOR pathway to inhibit OC progression, suggesting that HSP60 is a potential therapeutic target for OC treatment.
Multi-omics analyses reveal ClpP activators disrupt essential mitochondrial pathways in triple-negative breast cancer

Emily M. J. Fennell,Lucas J. Aponte-Collazo,Wimal Pathmasiri,Blake R. Rushing,Natalie K. Barker,Megan C. Partridge,Yuan-Yuan Li,Cody A. White,Yoshimi E. Greer,Laura E. Herring,Stanley Lipkowitz,Susan C. J. Sumner,Edwin J. Iwanowicz,Lee M. Graves

DOI: https://doi.org/10.3389/fphar.2023.1136317

IF: 5.6

2023-04-01

Frontiers in Pharmacology

Abstract:ClpP activators ONC201 and related small molecules (TR compounds, Madera Therapeutics), have demonstrated significant anti-cancer potential in vitro and in vivo studies, including clinical trials for refractory solid tumors. Though progress has been made in identifying specific phenotypic outcomes following ClpP activation, the exact mechanism by which ClpP activation leads to broad anti-cancer activity has yet to be fully elucidated. In this study, we utilized a multi-omics approach to identify the ClpP-dependent proteomic, transcriptomic, and metabolomic changes resulting from ONC201 or the TR compound TR-57 in triple-negative breast cancer cells. Applying mass spectrometry-based methods of proteomics and metabolomics, we identified ∼8,000 proteins and 588 metabolites, respectively. From proteomics data, 113 (ONC201) and 191 (TR-57) proteins significantly increased and 572 (ONC201) and 686 (TR-57) proteins significantly decreased in this study. Gene ontological (GO) analysis revealed strong similarities between proteins up- or downregulated by ONC201 or TR-57 treatment. Notably, this included the downregulation of many mitochondrial processes and proteins, including mitochondrial translation and mitochondrial matrix proteins. We performed a large-scale transcriptomic analysis of WT SUM159 cells, identifying ∼7,700 transcripts (746 and 1,100 significantly increasing, 795 and 1,013 significantly decreasing in ONC201 and TR-57 treated cells, respectively). Less than 21% of these genes were affected by these compounds in ClpP null cells. GO analysis of these data demonstrated additional similarity of response to ONC201 and TR-57, including a decrease in transcripts related to the mitochondrial inner membrane and matrix, cell cycle, and nucleus, and increases in other nuclear transcripts and transcripts related to metal-ion binding. Comparison of response between both compounds demonstrated a highly similar response in all -omics datasets. Analysis of metabolites also revealed significant similarities between ONC201 and TR-57 with increases in α-ketoglutarate and 2-hydroxyglutaric acid and decreased ureidosuccinic acid, L-ascorbic acid, L-serine, and cytidine observed following ClpP activation in TNBC cells. Further analysis identified multiple pathways that were specifically impacted by ClpP activation, including ATF4 activation, heme biosynthesis, and the citrulline/urea cycle. In summary the results of our studies demonstrate that ONC201 and TR-57 induce highly similar and broad effects against multiple mitochondrial processes required for cell proliferation.

pharmacology & pharmacy
Small Molecule ClpP-Agonists Block Mitochondrial GRSF1 Entry by Degrading Import Machinery

Andrei Mistreanu,Owen G. Canterbury,Emily M. Fennell,Sabrina C. Daglish,Paul R. Graves,Lee M. Graves

DOI: https://doi.org/10.1124/jpet.443.877640

2024-05-15

Journal of Pharmacology and Experimental Therapeutics

Abstract:ID 87764 Poster Board 443 Small molecule activators of the mitochondrial matrix protease, caseinolytic protease proteolytic subunit (ClpP), are under investigation for the treatment of aggressive and resilient cancers. Exemplified by the imipridones (ONC201/206, Chimerix), these and related analogs (TR compounds, Madera Therapeutics), disrupt multiple mitochondrial processes required for cancer cell growth. These ClpP agonists induce ClpP-dependent degradation of select matrix proteins, interrupting TCA cycle function, OXPHOS and mitochondrial metabolism, culminating in cancer cell senescence. Our investigation demonstrated that ClpP agonists also cause the degradation of select protein components of the mitochondrial import machinery known as the presequence translocase-associated motor (PAM) complex. Further experimentation demonstrated a concomitant cytosolic accumulation of the senescence-associated mitochondrial matrix protein GRSF1, indicating impairment of import. The goal of this study was to investigate how ClpP activation affects PAM complex proteins and how disruption of this translocase process impacts mitochondrial protein import and function. ClpP-dependent changes in mitochondrial protein abundance were investigated by immunoblotting. Subcellular localization of proteins was determined by manual fractionation of samples into mitochondrial and cytosolic fractions. Log fold changes in PAM complex protein levels were also determined via a global proteomics screen and quantitative peptide analysis using mass spectrometry. All experiments were done in wildtype, triple-negative breast cancer cells (TNBC cells: SUM159, MDA-MB-231) or their corresponding ClpP-knockout derivatives. Following ClpP-agonist treatment of TNBC cells, we detected a ~15 kDa increase in the molecular weight (MW) of the senescence-associated protein GRSF1 by immunoblot. This increase in MW was consistent with retention of the mitochondrial transit sequence (MTS), which is normally cleaved following import into the mitochondrial matrix. Subcellular fractionation revealed accumulation of the higher-weight GRSF1 (65 kDa) in the cytosolic fraction and a depletion of the lower-weight GRSF1 (50 kDa) from the mitochondrial fraction. Parallel proteomics data revealed a ClpP-agonist-dependent decrease in several PAM complex proteins (GRPEL1/2, TIMM44). The decline in GRPEL1 was validated by immunoblot analysis. Finally, the knockdown of specific PAM complex proteins was examined to confirm the effects of PAM complex protein loss on GRSF1 mitochondrial import. Our proteomics data that demonstrated a ClpP-dependent decrease in PAM complex proteins, suggested that mitochondrial protein import would be impaired. Following the fate of GRSF1, we confirmed this hypothesis and highlighted the importance of specific PAM complex proteins in this process. Similar MW shifts were observed with other mitochondrial matrix proteins (ALAS1, GPT2), suggesting broad effects of ClpP agonists on mitochondrial protein import. Previous studies showed that knockdown and inhibition of GRSF1's mitochondrial function was linked to increased senescence. Our data demonstrating ClpP-dependent inhibition of mitochondrial import suggests that this may be another mechanism by which ClpP agonists disrupt GRSF1 function and facilitate the development of senescence in TNBC. NIH GM ROI 138520 Drug-induced ClpP activation leads to PAM complex and mitochondrial matrix GRSF1 degradation

pharmacology & pharmacy
[Indication for correction osteotomy of the proximal femur].

P. Matzen

Abstract:
LONP1 regulation of mitochondrial protein folding provides insight into beta cell failure in type 2 diabetes

Jin Li,Jie Zhu,Yamei Deng,Emma C Reck,Emily M Walker,Vaibhav Sidarala,Dre L Hubers,Mabelle B Pasmooij,Chun-Shik Shin,Khushdeep Bandesh,Eftyhmios Motakis,Siddhi Nargund,Romy Kursawe,Venkatesha Basrur,Alexey Nesvizhskii,Michael L Stitzel,David Chan,Scott A Soleimanpour

DOI: https://doi.org/10.1101/2024.06.03.597215

2024-06-03

Abstract:Proteotoxicity is a contributor to the development of type 2 diabetes (T2D), but it is unknown whether protein misfolding in T2D is generalized or has special features. Here, we report a robust accumulation of misfolded proteins within the mitochondria of human pancreatic islets in T2D and elucidate its impact on β cell viability. Surprisingly, quantitative proteomics studies of protein aggregates reveal that human islets from donors with T2D have a signature more closely resembling mitochondrial rather than ER protein misfolding. The matrix protease LonP1 and its chaperone partner mtHSP70 were among the proteins enriched in protein aggregates. Deletion of LONP1 in mice yields mitochondrial protein misfolding and reduced respiratory function, ultimately leading to β cell apoptosis and hyperglycemia. Intriguingly, LONP1 gain of function ameliorates mitochondrial protein misfolding and restores human β cell survival following glucolipotoxicity via a protease-independent effect requiring LONP1-mtHSP70 chaperone activity. Thus, LONP1 promotes β cell survival and prevents hyperglycemia by facilitating mitochondrial protein folding. These observations may open novel insights into the nature of impaired proteostasis on β cell loss in the pathogenesis of T2D that could be considered as future therapeutic targets.

Cell Biology
Disuse-associated loss of the protease LONP1 in muscle impairs mitochondrial function and causes reduced skeletal muscle mass and strength

Zhisheng Xu,Tingting Fu,Qiqi Guo,Danxia Zhou,Wanping Sun,Zheng Zhou,Xinyi Chen,Jingzi Zhang,Lin Liu,Liwei Xiao,Yujing Yin,Yuhuan Jia,Erkai Pang,Yuncong Chen,Xin Pan,Lei Fang,Min-sheng Zhu,Wenyong Fei,Bin Lu,Zhenji Gan

DOI: https://doi.org/10.1038/s41467-022-28557-5

IF: 16.6

2022-02-16

Nature Communications

Abstract:Abstract Mitochondrial proteolysis is an evolutionarily conserved quality-control mechanism to maintain proper mitochondrial integrity and function. However, the physiological relevance of stress-induced impaired mitochondrial protein quality remains unclear. Here, we demonstrate that LONP1, a major mitochondrial protease resides in the matrix, plays a role in controlling mitochondrial function as well as skeletal muscle mass and strength in response to muscle disuse. In humans and mice, disuse-related muscle loss is associated with decreased mitochondrial LONP1 protein. Skeletal muscle-specific ablation of LONP1 in mice resulted in impaired mitochondrial protein turnover, leading to mitochondrial dysfunction. This caused reduced muscle fiber size and strength. Mechanistically, aberrant accumulation of mitochondrial-retained protein in muscle upon loss of LONP1 induces the activation of autophagy-lysosome degradation program of muscle loss. Overexpressing a mitochondrial-retained mutant ornithine transcarbamylase (ΔOTC), a known protein degraded by LONP1, in skeletal muscle induces mitochondrial dysfunction, autophagy activation, and cause muscle loss and weakness. Thus, these findings reveal a role of LONP1-dependent mitochondrial protein quality-control in safeguarding mitochondrial function and preserving skeletal muscle mass and strength, and unravel a link between mitochondrial protein quality and muscle mass maintenance during muscle disuse.

multidisciplinary sciences
The Role of Lonp1 on Mitochondrial Functions during Cardiovascular and Muscular Diseases

Giada Zanini,Valentina Selleri,Mara Malerba,Kateryna Solodka,Giorgia Sinigaglia,Milena Nasi,Anna Vittoria Mattioli,Marcello Pinti

DOI: https://doi.org/10.3390/antiox12030598

IF: 7.675

2023-03-01

Antioxidants

Abstract:The mitochondrial protease Lonp1 is a multifunctional enzyme that regulates crucial mitochondrial functions, including the degradation of oxidized proteins, folding of imported proteins and maintenance the correct number of copies of mitochondrial DNA. A series of recent studies has put Lonp1 at the center of the stage in the homeostasis of cardiomyocytes and muscle skeletal cells. During heart development, Lonp1 allows the metabolic shift from anaerobic glycolysis to mitochondrial oxidative phosphorylation. Knock out of Lonp1 arrests heart development and determines cardiomyocyte apoptosis. In adults, Lonp1 acts as a cardioprotective protein, as its upregulation mitigates cardiac injury by preventing the oxidative damage of proteins and lipids, and by preserving mitochondrial redox balance. In skeletal muscle, Lonp1 is crucial for cell development, as it mediates the activation of PINK1/Parkin pathway needed for proper myoblast differentiation. Skeletal muscle-specific ablation of Lonp1 in mice causes reduced muscle fiber size and strength due to the accumulation of mitochondrial-retained protein in muscle. Lonp1 expression and activity decline with age in different tissues, including skeletal muscle, and are associated with a functional decline and structural impairment of muscle fibers. Aerobic exercise increases unfolded protein response markers including Lonp1 in the skeletal muscle of aged animals and is associated with muscle functional recovery. Finally, mutations of Lonp1 cause a syndrome named CODAS (Cerebral, Ocular, Dental, Auricular, and Skeletal anomalies) characterized by the impaired development of multiple organs and tissues, including myocytes. CODAS patients show hypotonia and ptosis, indicative of skeletal muscle reduced performance. Overall, this body of observations points Lonp1 as a crucial regulator of mitochondrial functions in the heart and in skeletal muscle.

biochemistry & molecular biology,chemistry, medicinal,food science & technology
CLU (clusterin) and PPARGC1A/PGC1α coordinately control mitophagy and mitochondrial biogenesis for oral cancer cell survival

Prakash P. Praharaj,Srimanta Patra,Amruta Singh,Debasna P. Panigrahi,Hwa Y. Lee,Mohammad F. Kabir,Muhammad K. Hossain,Samir K. Patra,Birija S. Patro,Shankargouda Patil,Daniel J. Klionsky,Han J. Chae,Sujit K. Bhutia,Prakash P. PraharajSrimanta PatraAmruta SinghDebasna P. PanigrahiHwa Y. LeeMohammad F. KabirMuhammad K. HossainSamir K. PatraBirija S. PatroShankargouda PatilDaniel J. KlionskyHan J. ChaeSujit K. Bhutiaa Cancer and Cell Death Laboratory,Department of Life Science,National Institute of Technology Rourkela,Rourkela,Odisha,Indiab Department of Pharmacology,Jeonbuk National University Medical School,Jeonju,Jeonbuk,Republic of Koreac Department of Pharmacology,School of Medicine,Institute of New Drug Development,Jeonbuk National University,Jeonju,Republic of Koread School of Pharmacy,Jeonbuk National University,Jeonju,Jeonbuk,Republic of Koreae Laboratory of epigenetics,Department of Life Science,National Institute of Technology Rourkela,Rourkela,Odisha,Indiaf Bio-Organic Division,Bhabha Atomic Research Centre,Mumbai,Maharashtra,Indiag College of Dental Medicine,Roseman University of Health Sciences,South Jordan,UT,USAh Life Sciences Institute and Department of Molecular,Cellular and Developmental Biology,University of Michigan,Ann Arbor,MI,USAi Non-Clinical Evaluation Center,Biomedical Research Institute,Jeonbuk National University Hospital,Jeonju,Jeonbuk,Republic of Korea

DOI: https://doi.org/10.1080/15548627.2024.2309904

IF: 13.391

2024-03-08

Autophagy

Abstract:Mitophagy involves the selective elimination of defective mitochondria during chemotherapeutic stress to maintain mitochondrial homeostasis and sustain cancer growth. Here, we showed that CLU (clusterin) is localized to mitochondria to induce mitophagy controlling mitochondrial damage in oral cancer cells. Moreover, overexpression and knockdown of CLU establish its mitophagy-specific role, where CLU acts as an adaptor protein that coordinately interacts with BAX and LC3 recruiting autophagic machinery around damaged mitochondria in response to cisplatin treatment. Interestingly, CLU triggers class III phosphatidylinositol 3-kinase (PtdIns3K) activity around damaged mitochondria, and inhibition of mitophagic flux causes the accumulation of excessive mitophagosomes resulting in reactive oxygen species (ROS)-dependent apoptosis during cisplatin treatment in oral cancer cells. In parallel, we determined that PPARGC1A/PGC1α (PPARG coactivator 1 alpha) activates mitochondrial biogenesis during CLU-induced mitophagy to maintain the mitochondrial pool. Intriguingly, PPARGC1A inhibition through small interfering RNA (si PPARGC1A ) and pharmacological inhibitor (SR-18292) treatment counteracts CLU-dependent cytoprotection leading to mitophagy-associated cell death. Furthermore, co-treatment of SR-18292 with cisplatin synergistically suppresses tumor growth in oral cancer xenograft models. In conclusion, CLU and PPARGC1A are essential for sustained cancer cell growth by activating mitophagy and mitochondrial biogenesis, respectively, and their inhibition could provide better therapeutic benefits against oral cancer.

cell biology
LONP1 and mtHSP70 cooperate to promote mitochondrial protein folding

Chun-Shik Shin,Shuxia Meng,Spiros D. Garbis,Annie Moradian,Robert W. Taylor,Michael J. Sweredoski,Brett Lomenick,David C. Chan

DOI: https://doi.org/10.1038/s41467-020-20597-z

IF: 16.6

2021-01-11

Nature Communications

Abstract:Abstract Most mitochondrial precursor polypeptides are imported from the cytosol into the mitochondrion, where they must efficiently undergo folding. Mitochondrial precursors are imported as unfolded polypeptides. For proteins of the mitochondrial matrix and inner membrane, two separate chaperone systems, HSP60 and mitochondrial HSP70 (mtHSP70), facilitate protein folding. We show that LONP1, an AAA+ protease of the mitochondrial matrix, works with the mtHSP70 chaperone system to promote mitochondrial protein folding. Inhibition of LONP1 results in aggregation of a protein subset similar to that caused by knockdown of DNAJA3, a co-chaperone of mtHSP70. LONP1 is required for DNAJA3 and mtHSP70 solubility, and its ATPase, but not its protease activity, is required for this function. In vitro, LONP1 shows an intrinsic chaperone-like activity and collaborates with mtHSP70 to stabilize a folding intermediate of OXA1L. Our results identify LONP1 as a critical factor in the mtHSP70 folding pathway and demonstrate its proposed chaperone activity.

multidisciplinary sciences
Exposure assessment: serum levels of TCDD in Seveso, Italy.

L. Needham,P. Gerthoux,D. Patterson,P. Brambilla,S. J. Smith,E. Sampson,P. Mocarelli

DOI: https://doi.org/10.1006/ENRS.1998.3928

IF: 8.3

1999-02-01

Environmental Research

Abstract:Accurate exposure assessment is an important step in both risk assessment and epidemiologic studies involving potential human exposure to environmental toxicants. Various methods have been used to assess human exposure. These methods include models based on one's temporal and spatial nearness to the source, environmental levels of toxicant, and biological measures. We believe that the latter measure is the "gold standard." In this article we present the serum 2,3,7,8-tetrachlorodibenzo-p-dioxin levels in residents of the contaminated zones in Seveso, Italy, in 1976, and delineate these data by age and gender. Some of these serum levels are among the highest ever reported and thus this population serves as a benchmark for comparison of human exposure and potential adverse health effects. One such potential population is that population consuming potentially contaminated fish.
Polyphosphate and tyrosine phosphorylation in the N-terminal domain of the human mitochondrial Lon protease disrupts its functions

Nina Kunová,Gabriela Ondrovičová,Jacob A. Bauer,Veronika Krajčovičová,Matyáš Pinkas,Barbora Stojkovičová,Henrieta Havalová,Veronika Lukáčová,Lenka Kohútová,Július Košťan,Lucia Martináková,Peter Baráth,Jiří Nováček,Sebastian Zoll,Sami Kereϊche,Eva Kutejová,Vladimír Pevala

DOI: https://doi.org/10.1038/s41598-024-60030-9

IF: 4.6

2024-05-02

Scientific Reports

Abstract:Phosphorylation plays a crucial role in the regulation of many fundamental cellular processes. Phosphorylation levels are increased in many cancer cells where they may promote changes in mitochondrial homeostasis. Proteomic studies on various types of cancer identified 17 phosphorylation sites within the human ATP-dependent protease Lon, which degrades misfolded, unassembled and oxidatively damaged proteins in mitochondria. Most of these sites were found in Lon's N-terminal (NTD) and ATPase domains, though little is known about the effects on their function. By combining the biochemical and cryo-electron microscopy studies, we show the effect of Tyr186 and Tyr394 phosphorylations in Lon's NTD, which greatly reduce all Lon activities without affecting its ability to bind substrates or perturbing its tertiary structure. A substantial reduction in Lon's activities is also observed in the presence of polyphosphate, whose amount significantly increases in cancer cells. Our study thus provides an insight into the possible fine-tuning of Lon activities in human diseases, which highlights Lon's importance in maintaining proteostasis in mitochondria.

multidisciplinary sciences
Alpha-synuclein suppresses mitochondrial protease ClpP to trigger mitochondrial oxidative damage and neurotoxicity

Di Hu,Xiaoyan Sun,Xudong Liao,Xinwen Zhang,Sara Zarabi,Aaron Schimmer,Yuning Hong,Christopher Ford,Yu Luo,Xin Qi

DOI: https://doi.org/10.1007/s00401-019-01993-2

IF: 15.887

2019-03-15

Acta Neuropathologica

Abstract:Both α-Synuclein (αSyn) accumulation and mitochondrial dysfunction have been implicated in the pathology of Parkinson’s disease (PD). Although studies suggest that αSyn and its missense mutant, A53T, preferentially accumulate in the mitochondria, the mechanisms by which αSyn and mitochondrial proteins regulate each other to trigger mitochondrial and neuronal toxicity are poorly understood. ATP-dependent Clp protease (ClpP), a mitochondrial matrix protease, plays an important role in regulating mitochondrial protein turnover and bioenergetics activity. Here, we show that the protein level of ClpP is selectively decreased in αSyn-expressing cell culture and neurons derived from iPS cells of PD patient carrying αSyn A53T mutant, and in dopaminergic (DA) neurons of αSyn A53T mice and PD patient postmortem brains. Deficiency in ClpP induces an overload of mitochondrial misfolded/unfolded proteins, suppresses mitochondrial respiratory activity, increases mitochondrial oxidative damage and causes cell death. Overexpression of ClpP reduces αSyn-induced mitochondrial oxidative stress through enhancing the level of Superoxide Dismutase-2 (SOD2), and suppresses the accumulation of αSyn S129 phosphorylation and promotes neuronal morphology in neurons derived from PD patient iPS cells carrying αSyn A53T mutant. Moreover, we find that αSyn WT and A53T mutant interact with ClpP and suppress its peptidase activity. The binding of αSyn to ClpP further promotes a distribution of ClpP from soluble to insoluble cellular fraction in vitro and in vivo, leading to reduced solubility of ClpP. Compensating for the loss of ClpP in the substantia nigra of αSyn A53T mice by viral expression of ClpP suppresses mitochondrial oxidative damage, and reduces αSyn pathology and behavioral deficits of mice. Our findings provide novel insights into the mechanism underlying αSyn-induced neuronal pathology, and they suggest that ClpP might be a useful therapeutic target for PD and other synucleinopathies.

pathology,neurosciences,clinical neurology
LonP1 Links Mitochondria-ER Interaction to Regulate Heart Function.

Yujie Li,Dawei Huang,Lianqun Jia,Fugen Shangguan,Shiwei Gong,Linhua Lan,Zhiyin Song,Juan Xu,Chaojun Yan,Tongke Chen,Yin Tan,Yongzhang Liu,Xingxu Huang,Carolyn K Suzuki,Zhongzhou Yang,Guanlin Yang,Bin Lu

DOI: https://doi.org/10.34133/research.0175

2023-01-01

Abstract:Interorganelle contacts and communications are increasingly recognized to play a vital role in cellular function and homeostasis. In particular, the mitochondria-endoplasmic reticulum (ER) membrane contact site (MAM) is known to regulate ion and lipid transfer, as well as signaling and organelle dynamics. However, the regulatory mechanisms of MAM formation and their function are still elusive. Here, we identify mitochondrial Lon protease (LonP1), a highly conserved mitochondrial matrix protease, as a new MAM tethering protein. The removal of LonP1 substantially reduces MAM formation and causes mitochondrial fragmentation. Furthermore, deletion of LonP1 in the cardiomyocytes of mouse heart impairs MAM integrity and mitochondrial fusion and activates the unfolded protein response within the ER (UPR). Consequently, cardiac-specific LonP1 deficiency causes aberrant metabolic reprogramming and pathological heart remodeling. These findings demonstrate that LonP1 is a novel MAM-localized protein orchestrating MAM integrity, mitochondrial dynamics, and UPR, offering exciting new insights into the potential therapeutic strategy for heart failure.
Aberrant human ClpP activation disturbs mitochondrial proteome homeostasis to suppress pancreatic ductal adenocarcinoma

Pengyu Wang,Tao Zhang,Xinjing Wang,Hongying Xiao,Huiti Li,Lin-Lin Zhou,Teng Yang,Bingyan Wei,Zeyun Zhu,Lu Zhou,Song Yang,Xiongxiong Lu,Yonghui Zhang,Yue Huang,Jianhua Gan,Cai-Guang Yang

DOI: https://doi.org/10.1016/j.chembiol.2022.07.002

IF: 9.039

2022-09-15

Cell Chemical Biology

Abstract:The mitochondrial caseinolytic protease P (ClpP) is a target candidate for treating leukemia; however, the effects of ClpP modulation on solid tumors have not been adequately explored. Here, we report a potent activator of ClpP with the therapeutic potential for pancreatic ductal adenocarcinoma (PDAC). We first validated that aberrant ClpP activation leads to growth arrest of PDAC cells and tumors. We then performed high-throughput screening and synthetic optimization, from which we identified ZG111, a potent activator of ClpP. ZG111 binds to ClpP and promotes the ClpP-mediated degradation of respiratory chain complexes. This degradation activates the JNK/c-Jun pathway, induces the endoplasmic reticulum stress response, and consequently causes the growth arrest of PDAC cells. ZG111 also produces inhibitory effects on tumor growth in cell line-derived and patient-derived xenograft mouse models. Altogether, our data demonstrate a promising therapeutic strategy for PDAC suppression through the chemical activation of ClpP.

biochemistry & molecular biology
Targeting Mitochondrial DNA Transcription by POLRMT Inhibition or Depletion as a Potential Strategy for Cancer Treatment

Sabrina C. D. Daglish,Emily M. J. Fennell,Lee M. Graves

DOI: https://doi.org/10.3390/biomedicines11061598

IF: 4.757

2023-06-01

Biomedicines

Abstract:Transcription of the mitochondrial genome is essential for the maintenance of oxidative phosphorylation (OXPHOS) and other functions directly related to this unique genome. Considerable evidence suggests that mitochondrial transcription is dysregulated in cancer and cancer metastasis and contributes significantly to cancer cell metabolism. Recently, inhibitors of the mitochondrial DNA-dependent RNA polymerase (POLRMT) were identified as potentially attractive new anti-cancer compounds. These molecules (IMT1, IMT1B) inactivate cancer cell metabolism through reduced transcription of mitochondrially-encoded OXPHOS subunits such as ND1-5 (Complex I) and COI-IV (Complex IV). Studies from our lab have discovered small molecule regulators of the mitochondrial matrix caseinolytic protease (ClpP) as probable inhibitors of mitochondrial transcription. These compounds activate ClpP proteolysis and lead to the rapid depletion of POLRMT and other matrix proteins, resulting in inhibition of mitochondrial transcription and growth arrest. Herein we present a comparison of POLRMT inhibition and ClpP activation, both conceptually and experimentally, and evaluate the results of these treatments on mitochondrial transcription, inhibition of OXPHOS, and ultimately cancer cell growth. We discuss the potential for targeting mitochondrial transcription as a cancer cell vulnerability.

biochemistry & molecular biology,medicine, research & experimental,pharmacology & pharmacy

Extent of pathological damage to animals in a cold environment who are explosively decompressed.

Mitochondrial Lon Protease and Cancer.

The Mitochondrial Unfoldase-Peptidase Complex ClpXP Controls Bioenergetics Stress and Metastasis

Abstract 446: LONP1 inhibition induces mitochondrial proteotoxic stress and is cytotoxic to acute myeloid leukemia cells

Annual Meeting of the Pediatric Orthopaedic Society of North America, Miami, Florida, April 30-May 4, 1995.

Abstract 5898: Inhibition of the LONP1 ATPase domain induces mitochondrial proteotoxic stress and is cytotoxic to acute myeloid leukemia cells

HSP60-regulated Mitochondrial Proteostasis and Protein Translation Promote Tumor Growth of Ovarian Cancer

Multi-omics analyses reveal ClpP activators disrupt essential mitochondrial pathways in triple-negative breast cancer

Small Molecule ClpP-Agonists Block Mitochondrial GRSF1 Entry by Degrading Import Machinery

[Indication for correction osteotomy of the proximal femur].

LONP1 regulation of mitochondrial protein folding provides insight into beta cell failure in type 2 diabetes

Disuse-associated loss of the protease LONP1 in muscle impairs mitochondrial function and causes reduced skeletal muscle mass and strength

The Role of Lonp1 on Mitochondrial Functions during Cardiovascular and Muscular Diseases

CLU (clusterin) and PPARGC1A/PGC1α coordinately control mitophagy and mitochondrial biogenesis for oral cancer cell survival

LONP1 and mtHSP70 cooperate to promote mitochondrial protein folding

Exposure assessment: serum levels of TCDD in Seveso, Italy.

Polyphosphate and tyrosine phosphorylation in the N-terminal domain of the human mitochondrial Lon protease disrupts its functions

Alpha-synuclein suppresses mitochondrial protease ClpP to trigger mitochondrial oxidative damage and neurotoxicity

LonP1 Links Mitochondria-ER Interaction to Regulate Heart Function.

Aberrant human ClpP activation disturbs mitochondrial proteome homeostasis to suppress pancreatic ductal adenocarcinoma

Targeting Mitochondrial DNA Transcription by POLRMT Inhibition or Depletion as a Potential Strategy for Cancer Treatment